The cushing's syndrome market reached a value of USD 413.1 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 928.2 Million by 2035, exhibiting a growth rate (CAGR) of 7.67% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2024
|
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 413.1 Million |
Market Forecast in 2035
|
USD 928.2 Million |
Market Growth Rate 2025-2035 | 7.67% |
The Cushing's syndrome market has been comprehensively analyzed in IMARC's new report titled "Cushing's Syndrome Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Cushing's syndrome is a medical condition that develops when the body is exposed to high levels of cortisol for a prolonged period. Several factors, such as the use of oral corticosteroids, the development of a benign tumor on the pituitary gland, or a tumor on the adrenal glands, can contribute to the illness. The signs and symptoms of Cushing's syndrome are wide-ranging and can affect different parts of the body. Some of the common indications include weight gain, fatigue and muscle weakness, high blood pressure, increased thirst, frequent urination, etc. Cushing's syndrome can be diagnosed using a combination of medical history, physical examination, and laboratory investigations. The 24-hour urinary free cortisol test is often used to diagnose the ailment as it measures the amount of cortisol in the urine over a 24-hour period. Cortisol levels can also be measured through blood testing, and a dexamethasone suppression test can assist in identifying whether a tumor or the adrenal glands are responsible for the production of cortisol.
The increasing intake of corticosteroids, either as medication or as part of medical treatment for conditions such as asthma, rheumatoid arthritis, lupus, etc., is primarily augmenting the global Cushing's syndrome market. In addition to this, the widespread adoption of radiation therapy to reduce the size of a pituitary gland tumor or to treat an adrenal gland tumor that cannot be removed surgically is also bolstering the market growth. Moreover, the emerging popularity of minimally invasive surgical techniques, including laparoscopic adrenalectomy, on account of their several benefits over traditional open surgeries, such as shorter hospital stays, faster recovery period, and less postoperative pain, is acting as a significant growth-inducing factor. Apart from this, the increasing utilization of combination therapy, which involves surgical intervention, medical treatment, and lifestyle changes to effectively manage cortisol levels, is also creating a positive outlook for the market. Furthermore, the introduction of improved delivery methods for medications, including long-acting injections, for enhanced adherence to medication regimens and better control of cortisol levels is expected to drive the global Cushing's syndrome market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Cushing's syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Cushing's syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Cushing's syndrome market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current cushing's syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Isturisa (Osilodrostat) | Recordati |
Recorlev (Levoketoconazole) | Xeris Biopharma |
Korlym (Mifepristone) | Corcept Therapeutics |
Relacorilant | Corcept Therapeutics |
SPI62 | Sparrow Pharmaceuticals |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Cushing's Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies